Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
Wu X, Yang X, Xiong Y, Li R, Ito T, Ahmed TA, Karoulia Z, Adamopoulos C, Wang H, Wang L, Xie L, Liu J, Ueberheide B, Aaronson SA, Chen X, Buchanan SG, Sellers WR, Jin J, Poulikakos PI.
Wu X, et al. Among authors: chen x.
Nat Cancer. 2021 Apr;2(4):429-443. doi: 10.1038/s43018-021-00174-z. Epub 2021 Mar 1.
Nat Cancer. 2021.
PMID: 34568836
Free PMC article.
CDK4/6 inhibitors (CDK4/6i) are effective in metastatic breast cancer, but they have been only modestly effective in most other tumor types. Here we show that tumors expressing low CDK6 rely on CDK4 function, and are exquisitely sensitive to CDK4/6i. ...
CDK4/6 inhibitors (CDK4/6i) are effective in metastatic breast cancer, but they have been only modestly effective in most other tumor types. …